Figure 3.
Proportion of individuals achieving predefined lipid goals at A, week 24 and B, week 12 (intention‐to‐treat analysis; as‐planned study cohorts). Abbreviations: ALI, alirocumab; Apo, apolipoprotein; FA, fatty acids; LDL‐C, LDL cholesterol; LLT, lipid‐lowering therapy; non‐HDL‐C, non‐HDL cholesterol; UC, usual care. *P < .05; **P < .0001 vs control. Non‐HDL cholesterol: 2.6 mmol/L = 100 mg/dL; LDL cholesterol: 1.8 mmol/L = 70 mg/dL; ApoB: 0.8 g/L = 80 mg/dL